Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Pharma Deals, Investments and M&As in March 2018
If
the first two months of 2018 saw pharma and biotech firms receive more money
than what
al
FDA announces generic drug user fees for FY18; Gilead acquires Kite for US$ 12 billion
This week, Phispers brings you the FY18 user fee schedule under GDUFA II, posted by the USFDA, with
GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal
This week,
Phispers brings to you the details of the bioelectronics firm formed by GSK and
Google. T
Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?
Over
700 commonly used generic medicines were
recommended for suspension by the European Medic
Teva and Otsuka’s Multi-Billion dollar plan when blockbusters turn Generic: Deuterium Chemistry
Two blockbusters,
Otsuka’s
Abilify® (aripiprazole)
and Teva’s
Copaxone® (glatir
